The number of shares and votes in Vivesto AB (”Vivesto” or the ”Company”) has increased by 48,367,120 as a result of partial registration with the Swedish Companies Registration Office (Sw. Bolagsverket) of the new issue with preferential rights for the Company’s existing shareholders that was announced on 19 January 2022. The share capital has increased by SEK 4,836,712.
Today, the last trading day of the month, there are a total of 496,736,666 shares and votes in the Company. The share capital amounts to SEK 49,673,666.6.
For more information, contact:
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
Consilium Strategic Communications
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical- stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.